Severe Adverse Drug Reactions of Antidepressants: Results of the German Multicenter Drug Surveillance Program AMSP

The goal of the German drug safety program in psychiatry AMSP (Arzneimittelsicherheit in der Psychiatrie) is the assessment of severe or new adverse drug reactions (ADRs). Here we report on 53,042 of 122,562 patients treated with antidepressants who were monitored from 1993 to 2000 in 35 psychiatric hospitals in German-speaking countries. The overall incidence of severe ADRs of antidepressants was 1.4 % of exposed patients; when only ADRs rated as probable or definite were considered, a rate of 0.9 % in patients treated with antidepressants was observed.

ADR rates were higher for TCAs (imputed in 1.0 % of patients overall, respectively in 0.6 % of patients when only ADs were imputed) and lower for MAO inhibitors and SSRIs (0.7 % for both, respectively 0.3 % and 0.4 %). Within the TCA group there was a difference among clomipramine (2.1 %, respectively 1.0 %), amitriptyline (1.0 %, respectively 0.6 %), and doxepin or trimipramine (both 0.6 %, respectively 0.3 %). With regard to single SSRI, similar rates were observed for paroxetine (0.8 %, respectively 0.5 %) and for citalopram (0.7 %, respectively 0.4 %). Of the new dual-acting antidepressants, venlafaxine ranged at 0.9 %, (respectively 0.5 %) and mirtazapine at 0.6 % (respectively 0.5 %).

In particular, TCAs were associated with known risks, such as toxic delirium, grand mal seizures, and hepatic (i. e., increased liver enzymes), urologic (i. e., urinary retention), allergic (i. e., exanthema), or cardiovascular (i. e., mainly orthostatic collapse) reactions. In SSRI-treated patients (non-delirious) psychic and neurological ADRs were most prominent, followed by gastrointestinal, dermatologic, and endocrinological/electrolyte reactions, with agitation, hyponatremia (probably as part of the SIADH syndrome and associated with severe neurologic or psychiatric symptoms in 64 % of all cases), increased liver enzymes, nausea, and the serotonin syndrome as leading unwanted symptoms. Venlafaxine (in the immediate-release formulation) was associated with adverse CNS and somatic symptoms such as severe agitation, diarrhea, increased liver enzymes, hypertension, and hyponatremia. Mirtazapine was mostly connected with increased liver enzymes, cutaneous edema, and collapse, but with no case of significant hyponatremia. For drugs that potently inhibit serotonin uptake, serum sodium concentration should be controlled when applied in high-dose therapy or in vulnerable patients.

Key words

antidepressants - adverse drug reactions - drug surveillance - ADR - TCA - SSRI - MAO-I - mirtazapine - venlafaxine - SIADH - seizure - hyponatremia

References

• 1 Artigas F, Nutt D J, Shelton R. Mechanism of action of antidepressants.  Psychopharmacol Bull. 2002;  36 (Suppl 2) 123-132
• 2 Anderson I M, Tomenson B M. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis.  Brit Med J. 1995;  310 1433-1436
• 3 CPM P. Working Party on Efficacy of Medicinal Products: Note for Guidance Good Clinical Practice for Trials on Medicinal Products in the European Community.  Pharm Ind. 1990;  52 1476-1504
• 4 Corrigan O P. A risky business: the detection of adverse drug reactions in clinical trials and post-marketing exercises.  Soc Sci Med. 2002;  55 497-507
• 5 Grohmann R, Ströbel C h, Rüther E, Dirschedl P, Helmchen H, Hippius H, Müller-Oerlinghausen B, Schmidt L G, Wolf B. Adverse psychic reactions to psychotropic drugs - a report from the AMÜP study.  Pharmacopsychiatry. 1993;  26 84-93
• 6 Grohmann R, Rüther E, Engel R R, Hippius H. Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: methods and first results for tricyclic antidepressants and SSRI.  Pharmacopsychiatry. 1999;  32 21-28
• 7 Grohmann R, Hippius H, Helmchen H, Rüther E, Schmidt L G. The AMÜP study for drug surveillance in psychiatry - a summary of inpatient data.  Pharmacopsychiatry. 2004;  37 Suppl 1 S16-26
• 8 Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity.  Brit J Psychiatry. 1997;  170 120-127
• 9 Jick S S, Dean A D, Jick H. Antidepressants and suicide.  Brit Med J 1995. 28;  310 215-218
• 10 Kirby D, Ames D. Hyponatremia and selective serotonin re-uptake inhibitors in elderly patients.  Int J Geriatr Psychiatry. 2001;  16 484-493
• 11 Kropp S, Ziegenbein M, Grohmann R, Engel R, Degner D. Galactorrhea due to psychotropic drugs.  Pharmacopsychiatry. 2004;  37 Suppl 1 S84-88
• 12 Masood G R, Karki S D, Patterson W R. Hyponatremia with venlafaxine.  Ann Pharmacother. 1998;  32 49-51
• 13 Meynaar I A, Peeters A J, Mulder A H, Ottervanger J P. Syndrome of inappropriate ADH secretion attributed to the serotonin re-uptake inhibitors venlafaxine and paroxetine.  Neth J Med. 1997;  50 243-245
• 14 Montgomery S A, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, Clare A, Nutt D. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates.  Int Clin Psychopharmacol. 1994;  9 47-53
• 15 Montgomery S A. Safety of mirtazapine: A review.  Int Clin Psychopharmacol. 1995;  10 (Suppl 4) 37-45
• 16 Montgomery S A. A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression.  Int Clin Psychopharmacol. 2001;  16 163-178
• 17 Nutt D J. Tolerability and safety aspects of mirtazapine.  Hum Psychopharmacol. 2002;  17 (Suppl 1) S37-S41
• 18 Pollock B G. Adverse reactions of antidepressants in elderly patients.  J Clin Psychiatry. 1999;  60 (Suppl 20) 4-8
• 19 Rosenstein D L, Nelson J C, Jacobs S C. Seizures associated with antidepressants: a review.  J Clin Psychiatry. 1993;  54 289-299
• 20 Grohmann R, Engel R, Rüther E, Hippius H. The AMSP Drug Safety Program: Methods and Global Results.  Pharmacopsychiatry. 2004;  37 Suppl 1 S4-11
• 21 Schlienger R G, Klinik M H, Eggenberger C, Drewe J. Seizures associated with therapeutic doses of venlafaxine and trimipramine.  Ann Pharmacother. 2000;  34 402-405
• 22 Schmid C, Grohmann R, Engel R, Rüther E, Kropp S. Cardiac adverse effects associated with psychotropic drugs.  Pharmacopsychiatry. 2004;  37 Suppl 1 S65-69
• 23 Schmidt L G, Grohmann R, Müller-Oerlinghausen B, Ochsenfahrt H, Schönhöfer P S. Adverse drug reactions of first and second generation antidepressants - a critical evaluation of drug surveillance data.  Brit J Psychiatry. 1986;  148 38-43
• 24 Seidl L, Thornton G F, Smith J W. Studies on the epidemiology of adverse drug reaction.  Bull Johns Hopkins Hosp J. 1966;  119 299-315
• 25 Settle E C. Antidepressant drugs: disturbing and potentially dangerous adverse effects.  J Clin Psychiatry. 1998;  59 (Suppl 16) 25-30
• 26 Sternbach H. The serotonin syndrome.  Am J Psychiatry. 1991;  148 705-713
• 27 Stübner S, Grohmann R, Engel R, Bandelow B, Ludwig W -D, Wagner G, Müller-Oerlinghausen B, Möller H -J, Hippius H, Rüther E. Blood dyscrasias induced by psychotropic drugs.  Pharmacopsychiatry. 2004;  37 Suppl 1 S70-78
• 28 Stübner S, Rustenbeck E, Grohmann R, Wagner G, Engel R, Neundörfer G, Möller H -J, Hippius H, Rüther E. Severe and uncommon involuntary movement disorders due to psychotropic drugs.  Pharmacopsychiatry. 2004;  37 Suppl 1 S54-64
• 29 Van der Heijden P G, van Puijenbroek E P, van Buuren S, van der Hofstede J W. On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios.  Stat Med. 2002;  21 2027-2204